India, Aug. 25 -- Bengaluru-based MedGenome, India's leading genomic diagnostics and research services company, has announced the launch of the country's first CNS Tumour Methylation Classifier Test.

This diagnostic test can differentiate and classify over 90 classes of brain and central nervous system (CNS) tumours into accurate subtypes, enabling doctors to make optimal and accurate treatment decisions.

The test was unveiled in the presence of nearly 200 oncologists, neuro-onco surgeons and pathologists, researchers, and doctoral students at a precision oncology symposium in Mumbai, hosted by MedGenome jointly with Illumina, the global market leader in DNA sequencing and life sciences technologies.

Brain and CNS tumours are among the...